Compare ABUS & BZH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABUS | BZH |
|---|---|---|
| Founded | 2005 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 839.5M | 767.3M |
| IPO Year | 2008 | 1995 |
| Metric | ABUS | BZH |
|---|---|---|
| Price | $4.68 | $33.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $5.00 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 1.3M | 668.6K |
| Earning Date | 05-14-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.26 | N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | $14,083,000.00 | ★ $2,087,739,000.00 |
| Revenue This Year | N/A | $4.36 |
| Revenue Next Year | $239.71 | $10.79 |
| P/E Ratio | $5.45 | ★ N/A |
| Revenue Growth | ★ 128.21 | N/A |
| 52 Week Low | $3.35 | $17.83 |
| 52 Week High | $5.38 | $34.54 |
| Indicator | ABUS | BZH |
|---|---|---|
| Relative Strength Index (RSI) | 56.21 | 58.85 |
| Support Level | $4.11 | $31.67 |
| Resistance Level | $4.82 | $34.16 |
| Average True Range (ATR) | 0.15 | 0.63 |
| MACD | 0.03 | -0.22 |
| Stochastic Oscillator | 92.39 | 49.57 |
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Beazer Homes USA Inc is an construction company that focuses on residential construction. The company specializes in single-family housing and multi-unit building construction in states and metro markets. Beazer Homes builds homes and communities that target first-time, move-up, and luxury homebuyers with an average selling price of roughly $300,000. From a geographic perspective, home sales in the western and eastern United States have been the sources of revenue for the company. Its segments involve: West segment that includes Arizona, California, Nevada, and Texas; East segment that includes Delaware, Indiana, Maryland, Tennessee, and Virginia; and Southeast segment which includes Florida, Georgia, North Carolina, and South Carolina.